Expertise in
4
conditions

Romain Corre

CHU Rouen
Rouen, FR 
Expertise in
4
conditions
CHU Rouen
Rouen, FR 

Overview

Romain Corre practices practicing medicine in Rouen, France.

Mr. Corre is highly rated in 4 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, and Small Cell Lung Cancer (SCLC).

He is actively involved in clinical research, co-authoring 63 peer reviewed articles and participating in 7 clinical trials.

Gender

Male

Locations

CHU Rouen
Rouen, France
Other Locations
CHU Rennes
Rennes, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel To Dostarlimab + Docetaxel To Docetaxel Alone In Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed On Prior Anti-PD-(L)1 Therapy And Chemotherapy (COSTAR Lung)
A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel To Dostarlimab + Docetaxel To Docetaxel Alone In Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed On Prior Anti-PD-(L)1 Therapy And Chemotherapy (COSTAR Lung)
Enrollment Status: Active_not_recruiting
Publish Date: July 01, 2026
Intervention Type: Biological, Drug
Study Drugs: Cobolimab, Dostarlimab, Docetaxel
Study Phase: Phase 2/Phase 3
Observational Prospective Study of Quality of Life in Unresectable TNM Stage III NSCLC (OBSTINATE)
Observational Prospective Study of Quality of Life in Unresectable TNM Stage III NSCLC (OBSTINATE)
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2025
Intervention Type: Other
A Randomized Phase III Trial of OSE2101 Compared With Chemotherapy (Docetaxel or Pemetrexed) in HLA-A2 Positive Patients With Advanced Non-Small Cell Lung Cancer With Progressive Disease After Immune Checkpoint Inhibitors
A Randomized Phase III Trial of OSE2101 Compared With Chemotherapy (Docetaxel or Pemetrexed) in HLA-A2 Positive Patients With Advanced Non-Small Cell Lung Cancer With Progressive Disease After Immune Checkpoint Inhibitors
Enrollment Status: Terminated
Publish Date: February 02, 2024
Intervention Type: Drug, Biological
Study Drugs: OSE2101, Docetaxel, Pemetrexed
Study Phase: Phase 3
Randomized Phase III Study Testing Nivolumab and Ipilimumab Versus a Carboplatin Based Doublet in First Line Treatment of PS 2 or Elderly (More Than 70 Years Old) Patients With Advanced Non-small Cell Lung Cancer
Randomized Phase III Study Testing Nivolumab and Ipilimumab Versus a Carboplatin Based Doublet in First Line Treatment of PS 2 or Elderly (More Than 70 Years Old) Patients With Advanced Non-small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: March 01, 2023
Intervention Type: Drug
Study Drugs: Nivolumab+Ipilimumab, Chemotherapy
Study Phase: Phase 3
A Phase 3, Prospective, Randomized, Double-blind, Multi-center Study of the Efficacy and Safety of Lanreotide Autogel®/Depot 120 mg Plus BSC vs. Placebo Plus BSC for Tumour Control in Subjects With Well Differentiated, Metastatic and/or Unresectable, Typical or Atypical, Lung Neuroendocrine Tumours
A Phase 3, Prospective, Randomized, Double-blind, Multi-center Study of the Efficacy and Safety of Lanreotide Autogel®/Depot 120 mg Plus BSC vs. Placebo Plus BSC for Tumour Control in Subjects With Well Differentiated, Metastatic and/or Unresectable, Typical or Atypical, Lung Neuroendocrine Tumours
Enrollment Status: Terminated
Publish Date: July 06, 2022
Intervention Type: Drug
Study Phase: Phase 3
Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Etoposide and Carboplatin
Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Etoposide and Carboplatin
Enrollment Status: Completed
Publish Date: August 21, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and Hematology
BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and Hematology
Enrollment Status: Completed
Publish Date: November 06, 2019
View 6 Less Clinical Trials

63 Total Publications

Real-life management and outcomes of octogenarians with non-small-cell lung cancer: A 10-year evolution.
Real-life management and outcomes of octogenarians with non-small-cell lung cancer: A 10-year evolution.
Journal: European journal of cancer (Oxford, England : 1990)
Published: May 22, 2026

Frequently Asked Questions about Romain Corre

Is Romain Corre a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Romain Corre is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Romain Corre participate in research or clinical trials?

Yes. Romain Corre has published 63 articles and abstracts on conditions like Lung Cancer. You can view a list of Romain Corre's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Corre's expertise for a condition
ConditionClose
    View All 8 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile